JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio

The two cell therapy deals, announced at J.P. Morgan Healthcare Conference, gives BMS access to natural killer cell and t-cell research in blood and solid tumors. (Bristol Myers Squibb)

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.